American Oriental Bioengineering, Inc. (AOBI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2012 | -54.97 Million USD | -1450.55% |
| 2011 | -3.54 Million USD | -111.67% |
| 2010 | 30.36 Million USD | -48.32% |
| 2009 | 58.76 Million USD | -33.91% |
| 2008 | 88.9 Million USD | 70.23% |
| 2007 | 52.22 Million USD | 43.57% |
| 2006 | 36.37 Million USD | 98.35% |
| 2005 | 18.33 Million USD | 82.58% |
| 2004 | 10.04 Million USD | 76.3% |
| 2003 | 5.69 Million USD | 228.69% |
| 2002 | 1.73 Million USD | 4786.03% |
| 2001 | -36.99 Thousand USD | 95.56% |
| 2000 | -833.04 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2013 Q1 | -16.65 Million USD | -3589.55% |
| 2013 Q3 | -18.97 Million USD | -83.85% |
| 2013 Q2 | -10.32 Million USD | 38.04% |
| 2012 Q1 | -15.09 Million USD | 76.1% |
| 2012 FY | -54.97 Million USD | -1450.55% |
| 2012 Q4 | 477.32 Thousand USD | 102.49% |
| 2012 Q3 | -19.19 Million USD | 13.6% |
| 2012 Q2 | -22.21 Million USD | -47.25% |
| 2011 Q4 | -63.13 Million USD | -870.39% |
| 2011 FY | -3.54 Million USD | -111.67% |
| 2011 Q3 | 8.19 Million USD | 30.54% |
| 2011 Q2 | 6.27 Million USD | 13.24% |
| 2011 Q1 | 5.54 Million USD | -6.72% |
| 2010 Q2 | 9.08 Million USD | 42.64% |
| 2010 Q3 | 8.97 Million USD | -1.26% |
| 2010 Q4 | 5.94 Million USD | -33.75% |
| 2010 Q1 | 6.36 Million USD | -57.25% |
| 2010 FY | 30.36 Million USD | -48.32% |
| 2009 Q2 | 18.28 Million USD | 63.06% |
| 2009 FY | 58.76 Million USD | -33.91% |
| 2009 Q4 | 14.89 Million USD | -0.71% |
| 2009 Q1 | 11.21 Million USD | -5.2% |
| 2009 Q3 | 15 Million USD | -17.94% |
| 2008 FY | 88.9 Million USD | 70.23% |
| 2008 Q1 | 11.97 Million USD | -36.51% |
| 2008 Q4 | 11.82 Million USD | -45.85% |
| 2008 Q3 | 21.84 Million USD | 16.97% |
| 2008 Q2 | 18.67 Million USD | 55.95% |
| 2007 Q3 | 13.98 Million USD | 21.53% |
| 2007 Q4 | 18.86 Million USD | 34.92% |
| 2007 Q1 | 7.91 Million USD | -41.86% |
| 2007 FY | 52.22 Million USD | 43.57% |
| 2007 Q2 | 11.5 Million USD | 45.39% |
| 2006 Q4 | 13.6 Million USD | 45.51% |
| 2006 FY | 36.37 Million USD | 98.35% |
| 2006 Q3 | 9.35 Million USD | 33.5% |
| 2006 Q2 | 7 Million USD | 9.76% |
| 2006 Q1 | 6.38 Million USD | 2.78% |
| 2005 Q4 | 6.21 Million USD | 33.88% |
| 2005 Q1 | 3.02 Million USD | -23.49% |
| 2005 Q2 | 4.46 Million USD | 47.66% |
| 2005 Q3 | 4.63 Million USD | 3.86% |
| 2005 FY | 18.33 Million USD | 82.58% |
| 2004 Q3 | 2.65 Million USD | 43.06% |
| 2004 Q2 | 1.85 Million USD | 16.99% |
| 2004 Q1 | 1.58 Million USD | 32.55% |
| 2004 FY | 10.04 Million USD | 76.3% |
| 2004 Q4 | 3.95 Million USD | 49.05% |
| 2003 Q4 | 1.19 Million USD | -24.89% |
| 2003 Q1 | 1.42 Million USD | 125.85% |
| 2003 Q2 | 1.47 Million USD | 3.31% |
| 2003 Q3 | 1.59 Million USD | 7.96% |
| 2003 FY | 5.69 Million USD | 228.69% |
| 2002 Q3 | 357.81 Thousand USD | 316.61% |
| 2002 Q1 | - USD | -100.0% |
| 2002 FY | 1.73 Million USD | 4786.03% |
| 2002 Q4 | 631.95 Thousand USD | 76.61% |
| 2002 Q2 | -165.19 Thousand USD | 0.0% |
| 2001 Q2 | 35.52 Thousand USD | 150.43% |
| 2001 FY | -36.99 Thousand USD | 95.56% |
| 2001 Q4 | 13.37 Thousand USD | 179.85% |
| 2001 Q3 | -16.75 Thousand USD | -147.15% |
| 2001 Q1 | -70.45 Thousand USD | -34.52% |
| 2000 FY | -833.04 Thousand USD | 0.0% |
| 2000 Q1 | -366.77 Thousand USD | 0.0% |
| 2000 Q2 | -107.79 Thousand USD | 70.61% |
| 2000 Q3 | -306.1 Thousand USD | -183.97% |
| 2000 Q4 | -52.37 Thousand USD | 82.89% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -38913.219% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -7902.381% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -31952.07% |
| CytoDyn Inc. | -18.05 Million USD | -204.421% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 6.811% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -7605267.524% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -2926.579% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -989.752% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -183434.846% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -30190.303% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | -466.398% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 0.965% |
| SQZ Biotechnologies Company | -75.82 Million USD | 27.501% |
| Resverlogix Corp. | -12.74 Million USD | -331.19% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -14011.034% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 664.255% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -2138.911% |
| Mesoblast Limited | -84.14 Million USD | 34.671% |
| GB Sciences, Inc. | -1.42 Million USD | -3769.906% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -7902.381% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -208.02% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -1514.47% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -726.899% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -1635.088% |
| ContraFect Corporation | -56.88 Million USD | 3.369% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -1898.385% |
| BioStem Technologies, Inc. | -7.77 Million USD | -606.679% |
| LadRx Corporation | -3.82 Million USD | -1337.702% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -246.397% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -4812.632% |
| CSL Limited | 3.7 Billion USD | 101.485% |
| Biomind Labs Inc. | -1 Million USD | -5344.948% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -5802.248% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 167.161% |
| Nascent Biotech, Inc. | -2.22 Million USD | -2365.262% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 23.422% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 1218.504% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 1652.891% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -3478.815% |
| Marizyme, Inc. | -34.08 Million USD | -61.273% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -558.352% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -9634.393% |
| Zenith Capital Corp. | -8.94 Million USD | -514.697% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -1828.512% |
| Halberd Corporation | -75.05 Thousand USD | -73147.644% |
| Genus plc | 6.4 Million USD | 958.943% |
| Pharming Group N.V. | -4.87 Million USD | -1026.588% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -2667.326% |
| IMV Inc. | -38.67 Million USD | -42.152% |
| Affymax, Inc. | -15.04 Million USD | -265.362% |
| SYBLEU INC | -149.18 Thousand USD | -36749.683% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -5165.551% |
| Enzolytics Inc. | -2.14 Million USD | -2458.282% |
| argenx SE | -425.04 Million USD | 87.067% |
| AVAX Technologies, Inc. | 6.69 Million USD | 921.356% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -3821.021% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -4016.451% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -1367.331% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -218304.279% |
| Cell Source, Inc. | -4.32 Million USD | -1170.935% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -11279.98% |
| Q BioMed Inc. | -3.44 Million USD | -1495.429% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -1197.003% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -4276.78% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -1992.175% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -1106.93% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -1794.782% |
| Rebus Holdings, Inc. | -664 Thousand USD | -8178.969% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -5486.321% |
| Skye Bioscience, Inc. | -13.67 Million USD | -302.086% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -2848.575% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -2642.096% |
| ONE Bio Corp. | 13.68 Million USD | 501.799% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -2744.462% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -4786.84% |
| Agentix Corp. | -1.37 Million USD | -3907.444% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -1782.974% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -3380.684% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -315452.247% |
| Kadimastem Ltd | -3.04 Million USD | -1708.153% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -20903.781% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -13131.08% |
| NovAccess Global Inc. | -2.46 Million USD | -2128.525% |
| Itoco Inc. | -919.14 Thousand USD | -5880.847% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -24878.579% |
| Qrons Inc. | -643.67 Thousand USD | -8440.364% |
| Mobile Lads Corp. | -554.55 Thousand USD | -9812.967% |
| Genscript Biotech Corporation | -415.79 Million USD | 86.779% |
| International Stem Cell Corporation | -663 Thousand USD | -8191.457% |
| Bioxytran, Inc. | -3.82 Million USD | -1339.012% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -104330.769% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -270167.242% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -51.581% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -3297.55% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -7370.745% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -1667.032% |
| Neutra Corp. | -229.48 Thousand USD | -23854.558% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -213.429% |
| PureTech Health plc | -146.19 Million USD | 62.399% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -155.791% |
| IXICO plc | -1.43 Million USD | -3725.495% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -479.205% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 54.869% |
| CSL Limited | 3.81 Billion USD | 101.442% |
| Cellectis S.A. | -108.85 Million USD | 49.501% |